Possibly Hostile 'Alien' Object Could Arrive in November 2025, Wild Research Paper Says
The findings were reported by the New York Post, which wrote that the "inflammatory paper" was published on July 16 on the preprint server arXiv.
According to Live Science, the paper is controversial, was not peer-reviewed, and experts think its claims are "nonsense," however.
That site says that other scientists believe the object is natural.
3I/ATLAS was discovered on July 1 "barreling toward the sun at more than 130,000 mph (210,000 km/h)," and is a confirmed "interstellar object," according to Live Science, but "initial observations strongly suggest" it's a large comet "surrounded by a cloud of ice, gas and dust called a coma," the site reported.
The paper in question is titled, "Is the Interstellar Object 3I/ATLAS Alien Technology?" It was written by Adam Hibberd, Adam Crowl, and Abraham Loeb.
According to Live Science, Loeb is a Harvard University astronomer who is "renowned for linking extraterrestrial objects to intelligent aliens."
"At this early stage of its passage through our Solar System, 3I/ATLAS, the recently discovered interstellar interloper, has displayed various anomalous characteristics, determined from photometric and astrometric observations," the research trio wrote.
"As largely a pedagogical exercise, in this paper we present additional analysis into the astrodynamics of 3I/ATLAS, and hypothesize that this object could be technological, and possibly hostile as would be expected from the 'Dark Forest' resolution to the 'Fermi Paradox'. We show that 3I/ATLAS approaches surprisingly close to Venus, Mars and Jupiter..." the paper continued.
"Furthermore the low retrograde tilt of 3I/ATLAS's orbital plane to the ecliptic offers various benefits to an Extra-terrestrial Intelligence (ETI), since it allows the object access to our planet with relative impunity," they added. "The eclipse by the Sun from Earth of 3I/ATLAS at perihelion, would allow it to conduct a clandestine reverse Solar Oberth Manoeuvre, an optimal high-thrust strategy for interstellar spacecraft to brake and stay bound to the Sun."
The researchers noted: "An optimal intercept of Earth would entail an arrival in late November/early December of 2025."
Loeb wrote a blog post on the findings. "Today I co-authored an intriguing new paper with the brilliant collaborators Adam Hibberd and Adam Crowl from the Initiative for Interstellar Studies in London, UK," he wrote. "This new interstellar interloper has displayed a number of anomalous characteristics."
Possibly Hostile 'Alien' Object Could Arrive in November 2025, Wild Research Paper Says first appeared on Men's Journal on Jul 26, 2025
Solve the daily Crossword
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Alien worlds may not necessarily need water, scientists find: ‘We just opened a Pandora's box'
Water may not be essential to support life, and an entirely different type of liquid could do the same in alien worlds, a new study claims. Until now, water has been considered a requirement for life on other worlds, with scientists defining the habitability of other planets based on its presence. However, a new lab experiment suggests salts existing in liquid form at lower temperatures in other worlds may host life, though unlike anything resembling Earth's water-based beings. Such liquid-salts, called ionic liquids, can exist below about 100 degrees Celsius and remain stable enough in the fluid state at wider conditions to be a hospitable environment for life-signature molecules like proteins, say researchers from the Massachussets Institute of Technology. The study, published in the journal PNAS, theorises that even planets that are too warm, or those with atmospheres at pressures too low to host liquid water, could still support pockets of ionic liquid. 'We consider water to be required for life because that is what's needed for Earth life. But if we look at a more general definition, we see that what we need is a liquid in which metabolism for life can take place,' says Rachana Agrawal, an author of the study from MIT. 'Now if we include ionic liquid as a possibility, this can dramatically increase the habitability zone for all rocky worlds,' Dr Agrawal said. On Earth, such ionic liquids are mainly only made for industries, and do not occur naturally – except for one natural case. One liquid salt is generated from the mixing of venoms produced by two rival species of ants. In the new study, scientists sought to understand the broad conditions under which ionic liquids can be naturally produced, including the range of temperatures and pressures. They started by mixing sulphuric acid with 30 different nitrogen-containing organic compounds across several temperatures and pressures. Researchers then observed whether an ionic liquid formed when they evaporated away the sulphuric acid in various vials. This work was based on previous work suggesting that some of these chemicals, considered ingredients associated with life, are surprisingly stable in sulphuric acid. Scientists also mixed the ingredients onto basalt rocks, which are known to exist on the surface of many rocky planets. 'We were just astonished that the ionic liquid forms under so many different conditions,' says Sara Seager, another author of the study. 'If you put the sulphuric acid and the organic on a rock, the excess sulphuric acid seeps into the rock pores, but you're still left with a drop of ionic liquid on the rock. Whatever we tried, ionic liquid still formed,' Dr Seager says. Researchers found that their reactions produced ionic liquid at temperatures up to 180 degrees Celsius and at extremely low pressures – much lower than that of the Earth's atmosphere. The findings suggest ionic liquids can naturally form on other planets where liquid water cannot exist, under the right conditions. 'We're envisioning a planet warmer than Earth, that doesn't have water, and at some point in its past or currently, it has to have had sulphuric acid, formed from volcanic outgassing,' Dr Seager says. 'This sulphuric acid has to flow over a little pocket of organics. And organic deposits are extremely common in the solar system,' she explained. Scientists hope to conduct further studies to see what life-signature molecules might survive and thrive in ionic liquids. 'We just opened up a Pandora's box of new research. It's been a real journey,' Dr Seager said.
Yahoo
35 minutes ago
- Yahoo
MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results
Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric Cancer Department of Defense STTR Grant to advance INKTs in GVHD announced; program advancing New clinical grant awarded to launch AgenT-797 in GvHD clinical trial; target initiation 2H2025 NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced financial results for the second quarter ended June 30, 2025, and provided a business update highlighting major clinical achievements, a strengthened balance sheet, and expanded funding to advance both oncology and immunology programs. 'In Q2, we demonstrated the power of our platform with high impact clinical results, publication of key clinical findings, and competitive, non-dilutive, federal funding,' said Jennifer Buell, Ph.D., President and Chief Executive Officer of MiNK Therapeutics. 'Since quarter-end, we further strengthened our financial position that extends our runway beyond mid-2026. With our cash position, coupled with two separate non-dilutive grants for the clinical advancement of allo-INKTs in GvHD — we can achieve substantial clinical program advancements.' Highlights from Q2 2025 Durable Complete Remission in Metastatic Testicular Cancer: Nature's Oncogene publication of a landmark case of a patient with treatment-refractory metastatic testicular cancer who achieved a durable complete remission following a single infusion of agenT-797 (allo-INKTs) in combination with checkpoint blockade. The patient remains disease-free more than two years post-treatment. Strengthened Balance Sheet: Increased cash reserves extending runway beyond mid-2026 to advance clinical programs. Department of Defense STTR Grant Awarded for GvHD: Competitive DOD STTR grant awarded to advance development of iNKTs for graft-versus-host disease (GvHD) prevention and treatment; program launched. NEW Clinical Grant Awarded for GvHD: Additional clinical competitive grant awarded to initiate a first-in-human clinical trial of iNKTs in GvHD, with trial initiation targeted in 2H2025. Progress in Phase 2 Gastric Cancer Study: Phase 2 trial of agenT-797 in second-line gastric cancer anticipated additional clinical readouts in 2025. Peer-Reviewed Review of iNKT Cell Therapy: A Frontiers in Immunology featured MiNK's platform, highlighting iNKT cells' can remodel the tumor microenvironment and overcome therapeutic resistance, showcasing CAR-iNKTs, such as MiNK-215 as a next-generation solution for solid tumors. Financial Highlights Cash Position: MiNK ended Q2 2025 with approximately $1.6 million in cash and cash equivalents and subsequently raised $13 million through equity sales, providing expected runway into mid-2026. Net Loss: Net loss for Q2 2025 was $4.2 million, or $1.06 per share, compared to $2.7 million, or $0.73 per share for Q2 2024. For the first half of 2025, net loss was $7 million, or $1.76 per share compared to $6.5 million or $1.82 per share for the first half of 2024. Current period results reflect ongoing activity supporting our agent-797 programs and non-cash expenses including the impact of repricing of certain equity awards. Summary Consolidated Financial Information Condensed Consolidated Balance Sheet Data (in thousands) (unaudited) June 30, 2025 Cash and cash equivalents $ 1,682 Cash raised since quarter end 13,012 Other Financial Information (in thousands) (unaudited) Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Cash used in operations $ 1,569 $ 2,291 $ 2,910 $ 4,833 Non-cash expenses 1,501 491 2,336 1,141 Net loss 4,237 2,702 7,004 6,515 Net loss per share 1.06 0.73 1.76 1.82 Conference Call and Webcast Information MiNK will host a conference call and webcast on August 14, 2025, at 8:30 a.m. ET. To access the live call, please dial (800) 715-9871 (U.S.) or (646) 307-1963 (International) and reference conference ID 1149380. A live webcast and replay will be available in the Events & Presentations section of MiNK's investor website at About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels. Forward Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Investor Contact917-362-1370 | investor@ Contact781-674-4422 | communications@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025 NEW YORK, Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. "BrainStorm remains focused on executing our clinical development plan for NurOwn®. We reached an important milestone in Q2 with FDA clearance to initiate our Phase 3b trial, designed to generate confirmatory data to support a potential BLA submission," said Chaim Lebovits, President and CEO. "We are also advancing key operational activities, including discussions with clinical sites as well as ongoing engagement with our selected CDMO partners to ensure readiness for clinical drug supply. We are encouraged by the ongoing interest and support from clinicians and the ALS community, and we remain confident that, if approved, NurOwn has the potential to make a meaningful difference for patients and their families." Mr. Lebovits continued, "We support the FDA's consideration of the Citizen Petition, which may provide a fresh opportunity for an objective evaluation of the scientific evidence. We continue to stand behind the integrity and rigor of our data and will continue to engage with clinicians and the ALS community." Recent Highlights NurOwn (MSC-NTF) for ALS FDA has cleared the company to initiate the Phase 3b clinical trial of NurOwn® The Phase 3b trial, known as ENDURANCE, is expected to enroll approximately 200 participants at leading academic medical centers and will consist of a 24-week randomized, double-blind, placebo-controlled phase, followed by a 24-week open-label extension in which all participants will receive NurOwn. The primary endpoint is the change from baseline to week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R). Successful completion of the double blind portion of the study (Part A) is expected to generate the clinical data needed to support a new BLA submission. Details of the trial, including a list of anticipated participating clinical sites, are available on ID NCT06973629. A Citizens Petition submitted to the FDA by ALS Community requesting a new review of the NurOwn data The company acknowledges that the FDA's consideration of the petition provides a new opportunity to reaffirm NurOwn's potential as a therapy for ALS. BrainStorm was not involved in drafting or submitting this petition or its contents. New survival data from NurOwn Expanded Access Program show that 100% of participants (10/10) in the EAP survived more than 5 years from the onset of ALS symptoms, compared to published estimates indicating that approximately 10% of individuals with ALS would survive beyond 5 years. The single death in the cohort occurred following elective euthanasia. The median survival observed in the EAP cohort was 6.8 years (range: 6 to 7 years) from symptom onset. Although the EAP cohort included participants earlier in their disease course, these results are encouraging and support further study. Manufacturing Partnership with Minaris BrainStorm has signed a Letter of Intent (LOI) with Minaris Advanced Therapies, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, to manufacture NurOwn for the upcoming Phase 3b clinical trial. NurOwn® data selected as Breakthrough Science for Presentation at ISCT 2025 Meeting The new pharmacogenomic data were delivered in an oral presentation at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting in May 2025, in New Orleans. The data highlight the impact of the UNC13A genotype on clinical outcomes for ALS patients treated with NurOwn. The presentation was featured in the ISCT public announcement regarding the meeting, which indicated that the data were "carefully reviewed and selected by the ISCT 2025 Planning Faculty, to explore the latest breakthroughs in the clinical translation of Mesenchymal Stem/Stromal Cells and how they will shape the future of cell therapies." Financial Results for the Second quarter Ended June 30, 2025 Cash, cash equivalents, and restricted cash were approximately $1.03 million as of June 30, 2025. Research and development expenditures, net, for the quarter ended June 30, 2025 were $1.1 million, compared to $0.9 million for the quarter ended June 30, 2024. General and administrative expenses for the quarter ended June 30, 2025 were approximately $1.4 million, compared to approximately $2.1 million for the quarter ended June 30, 2024. Net loss for the quarter ended June 30, 2025, was approximately $2.9 million, as compared to a net loss of approximately $2.5.4 million for the quarter ended June 30, 2024. Net loss per share for the three months ended June 30, 2025, and 2024 was $0.34 and $0.60, respectively. Conference Call and Webcast Participant Numbers: Toll Free 877-545-0320 International 973-528-0002 Participant Access Code 601260 Webcast The replay of the conference call can be accessed by dialing the numbers below and will be available until August 28. Replay Numbers: Toll Free 877-481-4010 International 919-882-2331 Reply Passcode 52831 About NurOwn® The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection. NurOwn® is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the "Floor Effect" — a critical challenge in measuring clinical outcomes in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging area of regenerative medicine. To learn more, visit Notice Regarding Forward-Looking Statements This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), Special Protocol Assessment (SPA), the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. CONTACTS Investors:Michael WoodPhone: +1 646-597-6983mwood@ Media: Uri Yablonka, Chief Business OfficerPhone: +1 917-284-2911uri@ CELL THERAPEUTICS INC. AND SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands (Except share data) June 30,December 31, 20252024 UnauditedAudited U.S. $ in thousands ASSETSCurrent Assets: Cash and cash equivalents$ 824$ 187 Other accounts receivable 106 63 Prepaid expenses and other current assets 585 135 Total current assets$ 1,515$ 385Long-Term Assets: Prepaid expenses and other long-term assets $ 24$ 22 Restricted Cash 201 184 Operating lease right of use asset (Note 3) 495 807 Property and Equipment, Net 331 434 Total Long-Term Assets$ 1,051$ 1,447Total assets$ 2,566$ 1,832LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)Current Liabilities: Accounts payables$ 5,997$ 6,080 Accrued expenses 367 619 Short-term loans (Note 7) 101 300 Operating lease liability (Note 3) 381 549 Employees related liability 1,682 1,430 Total current liabilities$ 8,528$ 8,978Long-Term Liabilities: Operating lease liability (Note 3) 95 171 Warrants liability (Note 4) - 447 Total long-term liabilities$ 95$ 618Total liabilities$ 8,623$ 9,596Stockholders' Deficit: Stock capital: (Note 5) 16 14 Common Stock of $0.00005 par value - Authorized: 250,000,000 shares at June 30, 2025 and at December 31, 2024 respectively; Issued and outstanding: 10,120,109 and 6,141,762 shares at June 30, 2025 and December 31, 2024 respectively Additional paid-in-capital 226,446 218,974 Treasury stocks (116) (116) Accumulated deficit (232,403) (226,636) Total stockholders' deficit$ (6,057)$ (7,764)Total liabilities and stockholders' deficit$ 2,566$ 1,832 BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) U.S. dollars in thousands (Except share data) Six months ended Three months ended June 30, June 30, 2025202420252024 UnauditedUnaudited Operating expenses:Research anddevelopment, net$ 2,424$ 1,883$ 1,120$ 922 General and administrative 3,238 3,573 1,453 2,060Operating loss (5,662) (5,456) (2,573) (2,982)Financial income (expense), net (284) 43 (330) 30Gain (loss) on change in fair value of Warrants liability (Note 4) 179 529 - (411)Net loss$ (5,767)$ (5,942)$ (2,903)$ (2,541)Basic and diluted net lossper share from continuing operations$ (0.77)$ (1.35)$ (0.34)$ (0.60)Weighted average numberof shares outstanding usedin computing basic and diluted net loss per share 7,487,495 4,531,801 8,620,400 4,747,699 Logo - View original content to download multimedia: SOURCE BrainStorm Cell Therapeutics Inc.
